Of the checkpoint blockade antibodies, anti-CTLA-4 applied as monotreatment induced a tumor growth delay on the primary as well as the distant tumor and, consequently, on the total tumor burden that outperfomed AU-011 as a monotreatment (Fig. 6c). This evidence concerns the gene CTLA4 and neoplasm.